Recurrent coronary syndromes in a patient with isolated very-high lipoprotein (a) and the prothrombin genetic variant rs1799963 (G20210A): a case report.

Acute coronary syndromes Case report Lipoprotein (a) Prothrombin

Journal

European heart journal. Case reports
ISSN: 2514-2119
Titre abrégé: Eur Heart J Case Rep
Pays: England
ID NLM: 101730741

Informations de publication

Date de publication:
Mar 2019
Historique:
received: 13 09 2018
accepted: 07 02 2019
entrez: 26 4 2019
pubmed: 26 4 2019
medline: 26 4 2019
Statut: epublish

Résumé

Elevated lipoprotein (a) [Lp(a)] is an under-diagnosed genetically inherited risk factor for coronary heart disease (CHD) and calcific aortic valve stenosis. Premature myocardial infarction (MI) could stem from the association between elevated Lp(a) and other non-traditional cardiovascular risk factors. Here, we report a male patient with extremely high Lp(a) plasma levels [610 nmol/L (244 mg/dL); normal <75 nmol/L (<30 mg/dL)] associated with the The rare association between extremely elevated circulating Lp(a) levels and prothrombotic genetic variants of coagulation factors appears to be a deadly combination that can only be adequately treated by antiplatelet therapy and lipoprotein apheresis.

Sections du résumé

BACKGROUND BACKGROUND
Elevated lipoprotein (a) [Lp(a)] is an under-diagnosed genetically inherited risk factor for coronary heart disease (CHD) and calcific aortic valve stenosis. Premature myocardial infarction (MI) could stem from the association between elevated Lp(a) and other non-traditional cardiovascular risk factors.
CASE SUMMARY METHODS
Here, we report a male patient with extremely high Lp(a) plasma levels [610 nmol/L (244 mg/dL); normal <75 nmol/L (<30 mg/dL)] associated with the
DISCUSSION CONCLUSIONS
The rare association between extremely elevated circulating Lp(a) levels and prothrombotic genetic variants of coagulation factors appears to be a deadly combination that can only be adequately treated by antiplatelet therapy and lipoprotein apheresis.

Identifiants

pubmed: 31020261
doi: 10.1093/ehjcr/ytz019
pii: ytz019
pmc: PMC6439380
doi:

Types de publication

Case Reports

Langues

eng

Pagination

ytz019

Références

N Engl J Med. 2013 Sep 19;369(12):1115-23
pubmed: 23991625
Circulation. 2014 Feb 11;129(6):635-42
pubmed: 24243886
J Am Coll Cardiol. 2017 Feb 14;69(6):692-711
pubmed: 28183512
Lancet Diabetes Endocrinol. 2017 Apr;5(4):280-290
pubmed: 28215937
Eur Heart J. 2017 May 21;38(20):1561-1569
pubmed: 28453721
Sci Rep. 2017 Oct 19;7(1):13550
pubmed: 29051591
Arterioscler Thromb Vasc Biol. 2018 Mar;38(3):592-598
pubmed: 29284604
JAMA Cardiol. 2018 Jul 1;3(7):619-627
pubmed: 29926099

Auteurs

Ilya Khantalin (I)

Université de La Réunion, Inserm, UMR 1188 DéTROI, Plateforme CYROI, 2 Rue Maxime Rivière, Sainte-Clotilde, France.
CHU de La Réunion, Service de Chirurgie Vasculaire, Allée des Topazes, Saint-Denis, France.

Valentin Blanchard (V)

Université de La Réunion, Inserm, UMR 1188 DéTROI, Plateforme CYROI, 2 Rue Maxime Rivière, Sainte-Clotilde, France.

Nicolas Viallet (N)

CHU de La Réunion, Service de Néphrologie, Allée des Topazes, Saint-Denis, France.

Gilles Lambert (G)

Université de La Réunion, Inserm, UMR 1188 DéTROI, Plateforme CYROI, 2 Rue Maxime Rivière, Sainte-Clotilde, France.

Classifications MeSH